

PRESS RELEASE

innate pharma

INNATE PHARMA'S ANNUAL GENERAL MEETING OF JUNE 29, 2011: ALL PROPOSED RESOLUTIONS WERE VOTED ACCORDING TO MANAGEMENT'S RECOMMENDATIONS


Marseilles, France, June 29, 2011

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its Annual General Meeting (“AGM”) which took place on June 29, 2011, in Marseilles, France.

A number of 26,483,176 votes were expressed out of a total of 37,568,383 shares with voting rights, representing a quorum of 70.5%. All resolutions were voted in accordance with the management’s recommendations. Details of the votes are available on Innate Pharma’s website, [“investors section”](#).

During the AGM, the Board members mandates were renewed and Alta BioPharma Partners II, LP, represented by Ms Ekaterina Smirnyagina, was appointed as a new member of the Supervisory Board.

The AGM was followed by a meeting of the Supervisory Board on the same day, which appointed Mr Gilles Brisson as Chairman and Ms Irina Staatz-Granzer as Vice-Chairman of the Supervisory Board.



PRESS RELEASE

innate pharma

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal antibody potentiating NK cells activation currently in Phase II clinical trials in hematologic cancers. Two of its antibody programs in chronic inflammation are out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody technology. The Company has implemented in-house a large panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics and pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to a very large set of unique research tools in cellular immunology through its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 85 employees as at March 31, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Laure-Hélène Mercier
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com

Alize Public Relations
Caroline Carmagnol
Phone: +33 (0)1 42 68 86 43
Mobile: +33 (0)6 64 18 99 59
caroline@alizerp.com